JMY (junction mediating and regulatory protein, p53 cofactor ) Blocking Peptide (the N terminal of JMY)(100ug)

This is a synthetic peptide designed for use in combination with anti-JMY Antibody (ARP64775_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

Prices direct from Aviva Systems Biology Incorporated

Quick response times

Exclusive Absave savings/discounts

SPECIFICATIONS

Size

100ug

Reactivities

Hum

Format

Lyophilized powder

Presku

AAP64775

Target

JMY acts both as a nuclear p53/TP53-cofactor and a cytoplasmic regulator of actin dynamics depending on conditions. In nucleus, JMY acts as a cofactor that increases p53/TP53 response via its interaction with p300/EP300. JMY increases p53/TP53-dependent transcription and apoptosis, suggesting an important role in p53/TP53 stress response such as DNA damage. In cytoplasm, JMY acts as a nucleation-promoting factor for both branched and unbranched actin filaments. JMY activates the Arp2/3 complex to induce branched actin filament networks. JMY also catalyzes actin polymerization in the absence of Arp2/3, creating unbranched filaments. JMY contributes to cell motility by controlling actin dynamics. JMY may promote the rapid formation of a branched actin network by first nucleating new mother filaments and then activating Arp2/3 to branch off these filaments. The p53/TP53-cofactor and actin activator activities are regulated via its subcellular location.

Weight

82kDa

Gene Id

133746

Alternative Names

FLJ37870; MGC163496; WHDC1L3